About

Lorme

QLIFE HOLDING AB

Qlife Holding AB is a med-tech group that strives to revolutionize the market for clinical biomarker and virus tests. By enabling tests at home as a complement to tests in healthcare, access to important health information is facilitated, which can contribute to better treatment and potentially prevent diseases.

Qlife Holding was formed in October 2019 and received the certification ISO 13485:2016 the same year, which means that Qlife meets all requirements for the manufacture and sale of in-vitro diagnostic analyzers and reagents. The first capsules in the company's product, Egoo.Health Platform, were CE marked for professional use in early 2020. The company has patent protection for key parts of its technology.
 

Egoo.Health Platform

Qlife's product Egoo.Health Platform is an integrated platform with a measuring instrument with disposable capsules and software, where each capsule contains a test for a specific biomarker or virus. The system can be used both at home and in the laboratory as well as in point of care environments.

On March 2, 2020, Qlife Holding completed a listing on the Nasdaq First North Growth Market, Stockholm. The company currently has about 40 employees.

Qlife was founded by Thomas Warthoe, Lars Bangsgaard and Ebbe Finding, who are all still active in the company. The founding team has over 20 years of experience in the med-tech industry and has, among other things, developed high-tech IVD (In vitro diagnostics) units in collaboration with major international companies.
 

Strategy and Vision

In the long term, the goal is to expand into the growing consumer market for self-testing, and thus give everyone the opportunity for greater insight into their own health. The strategy is to initially launch the products in the Nordic countries, followed by the rest of Europe, the USA and the rest of the world. In the short term, the system will be launched in well-defined segments of chronically ill patients where there is a great need for frequent monitoring. Qlife will continuously develop additional biomarkers for use in various disease areas and health conditions.